The KRAS-variant is a Biomarker of Cetuximab Response and Altered Immunity in Head and Neck Cancer: NRG Oncology/RTOG 0522

Publication date: 1 December 2016
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 96, Issue 5
Author(s): J.B. Weidhaas, J. Harris, D. Schaue, A.M. Chen, R.K. Chin, R. Axelrod, A.K. El-Naggar, A.K. Singh, T.J. Galloway, D. Raben, D. Wang, C.L. Matthiesen, V. Avizonis, R. Manon, O. Yumen, P.F. Nguyen-Tan, A. Trotti, H.D. Skinner, Q. Zhang, J. Sayre, R.L. Ferris, D. Sidransky, C. Chung




http://ift.tt/2hhwC5q